Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Edgewise Therapeutics Inc shares valued at $4,804,322 were purchased by ROBERT MICHAEL CARRUTHERS on Jan 15 ’26. At $26.56 per share, ROBERT MICHAEL CARRUTHERS acquired 180,872 shares.
Also, ROBERT MICHAEL CARRUTHERS purchased 116,665 shares, netting a total of over 3,039,812 in proceeds.
Before that, ROBERT MICHAEL CARRUTHERS had added 70,000 shares to its account. In a trade valued at $1,566,586, the Officer bought Edgewise Therapeutics Inc shares for $22.38 each.
As published in their initiating research note from Goldman on September 25, 2025, Edgewise Therapeutics Inc [EWTX] has been a Neutral and the price target has been revised to $20. Analysts at Raymond James started covering the stock with ‘”a Strong buy”‘ outlook in a report released in late July. As of June 30, 2025, H.C. Wainwright has initiated its “Buy” rating for EWTX. Earlier on April 30, 2025, Guggenheim initiated its rating. Their recommendation was “a Buy” for EWTX stock.
Analyzing EWTX Stock Performance
On last trading session, Edgewise Therapeutics Inc [NASDAQ: EWTX] plunged -5.57% to $26.6. The stock’s lowest price that day was $26.06, but it reached a high of $28.0 in the same session. During the last five days, there has been a surge of approximately 6.53%. Over the course of the year, Edgewise Therapeutics Inc shares have dropped approximately -3.34%.
Support And Resistance Levels for Edgewise Therapeutics Inc (EWTX)
RSI (Relative Strength Index) is 57.60 on the 14-day chart, showing neutral technical sentiment.
Is Edgewise Therapeutics Inc subject to short interest?
Stocks of Edgewise Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.54 million shares to 11.69 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 11.15 million shares. A jump of 4.61% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.06 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.06.
Which companies own the most shares of Edgewise Therapeutics Inc (EWTX)?
In terms of Edgewise Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, down nearly -29.0% from the previous closing price of $28.17. Analysts anticipate Edgewise Therapeutics Inc stock to reach 20 by 2026, with the lowest price target being 20. In spite of this, 1 analysts ranked Edgewise Therapeutics Inc stock as Buy at the end of 2026. On April 02, 2025, Scotiabank assigned a price target of “a Sector perform” to the stock and downgraded coverage with a $14.
